We therefore tested the effects of the TRPV4 antagonist GSK219 on the levels of sepsis-induced circulating cytokines, measuring serum concentrations 3 and 18 hours after LPS injection in control (LPS alone) and GSK219-pretreated (LPS + GSK219) mice. This evidence concerns the gene TRPV4 and Sepsis.